Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
Holding PMVP?
Track your performance easily
PMVP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $3.47
Previous Close$1.58
Volume142.60K
Average Volume (3M)204.34K
Market Cap
$81.76M
Enterprise Value-$87.81M
Total Cash (Recent Filing)$182.84M
Total Debt (Recent Filing)$13.27M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Feb 26, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding51,747,130
10 Day Avg. Volume279,138
30 Day Avg. Volume204,335
Standard Deviation0.23
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.16
Forecast
1Y Price Target
$6.00Price Target Upside284.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
PMV Pharmaceuticals News
PremiumCompany Announcements
PMV Pharmaceuticals Initiates Strategic Lease Termination
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy remains on track, with more than 75% of sites activated across the US, Europe, and Asia-Pacific.
Drug EfficacyMeaningful response rates were seen in ovarian, breast, small-cell lung, and endometrial cancer types.
Financial PerformancePMV recorded a net loss of $0.02 per share—much narrower than previously estimated net loss of $0.31 per share.
Bears Say
Clinical RisksRisks include negative PC14586 clinical data, delays in moving candidates into advanced trials, and setbacks in later stage studies.
Clinical TrialsThe Keytruda combo arm of PYNNACLE was discontinued due to limited clinical benefit.
Drug DeploymentThere is a low probability of PC14586 monotherapy deployment in a tumor-agnostic fashion.
---
Ownership Overview
2.76% Insiders
8.87% Mutual Funds
50.87% Other Institutional Investors
33.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $1.40 and its highest was $3.47 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
Currently, no data Available
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.346 by -$0.024.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -$0.36.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 51,747,130 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.346. Following the earnings report the stock price went up 7.229%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Among the largest hedge funds holding PMV Pharmaceuticals’s share is Baker Bros Advisors LP. It holds PMV Pharmaceuticals’s shares valued at 480K.
---
PMV Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (284.62% Upside)
$6.00 (284.62% Upside)
Blogger Sentiment
Bullish
PMVP Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.14%
12-Months-Change
Fundamentals
Return on Equity
-23.63%
Trailing 12-Months
Asset Growth
-14.38%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
---
PMVP Stock 12 Month Forecast
Average Price Target
$6.00
▲(284.62% Upside)
Technical Analysis
Best Analysts Covering PMVP
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-21.02%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -21.02% per trade.
---